ABK-CDK4 / Abbisko - LARVOL DELTA

Discovery of ABK-CDK4, a selective and brain-penetrant CDK4 inhibitor (AACR 2026) - "Although the first generation dual CDK4/6 inhibitors— such as palbociclib, ribociclib, and abemaciclib—have demonstrated clinical efficacy in advanced breast cancer, inhibition of CDK6 would cause dose-limiting hematological toxicity. ABK-CDK4, developed by Abbisko Therapeutics, is a highly selective and brain-penetrant CDK4 inhibitor with the potential to address limitations of current CDK4/6 inhibitors. Its promising efficacy, selectivity, and other properties support further preclinical advancement toward clinical development."

Breast Cancer • Eye Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Retinoblastoma • Solid Tumor